The Relationship Between Plasma Osteoprotegerin and Endothelium-Dependent Arterial Dilation in Type 2 Diabetes
Authors:
Open Access
- 1 July 2006
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 55 (7) , 2126-2131
Abstract
Osteoprotegerin is a recently identified inhibitor of bone resorption. Recent studies indicate that osteoprotegerin also acts as an important regulatory molecule in the vasculature. The purpose of this study was to investigate the relationship between plasma osteoprotegerin levels and endothelium-dependent arterial dilation in type 2 diabetic patients. The study subjects included 40 newly diagnosed type 2 diabetic patients and 46 healthy subjects. All patients were given insulin therapy for 6 months. Plasma osteoprotegerin concentration was measured in duplicate by a sandwich enzyme-linked immunosorbent assay method, and high-resolution ultrasound was used to measure brachial artery diameter at rest, after reactive hyperemia, and after sublingual glyceryltrinitrate. The plasma osteoprotegerin level in patients before treatment was 3.36 ± 0.32 ng/l, which was significantly higher than that in control subjects (2.38 ± 0.25 ng/l, P < 0.001). After 6 months of treatment, osteoprotegerin levels decreased markedly (2.83 ± 0.34 ng/l, P < 0.001). Flow-mediated endothelium-dependent arterial dilation in patients before treatment was 3.21 ± 0.52%, which was significantly lower than that in control subjects (4.46 ± 0.56%, P < 0.01), and it improved markedly after 6 months of treatment (4.03 ± 0.49%, P < 0.01). In multivariate analysis, osteoprotegerin was significantly associated with endothelium-dependent arterial dilation, fasting blood glucose (FBG), HbA1c (A1C), and ultrasensitive C-reactive protein (CRP) at baseline (P < 0.01). The absolute changes in osteoprotegerin showed significant correlation with changes in endothelium-dependent arterial dilation, FBG, A1C, and CRP in diabetic patients during the course of treatment (P < 0.01). This study shows that plasma osteoprotegerin levels are elevated in newly diagnosed diabetic patients and are significantly associated with endothelial function.Keywords
This publication has 24 references indexed in Scilit:
- Osteoprotegerin Is Associated With Silent Coronary Artery Disease in High-Risk but Asymptomatic Type 2 Diabetic PatientsDiabetes Care, 2005
- Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complicationsEuropean Journal of Endocrinology, 2003
- Increased Osteoprotegerin Serum Levels in Men with Coronary Artery DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2003
- Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery DiseaseCirculation, 2002
- PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathwaysFEBS Letters, 2002
- Differential Expression of Bone Matrix Regulatory Proteins in Human Atherosclerotic PlaquesArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Associations of Serum Osteoprotegerin Levels with Diabetes, Stroke, Bone Density, Fractures, and Mortality in Elderly WomenThe Journal of Clinical Endocrinology & Metabolism, 2001
- Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial CellsJournal of Biological Chemistry, 2000
- osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcificationGenes & Development, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997